1. In Vivo
  2. >>Archive

PSA 2004: Looking to the Sustainable Middle

If the nominal theme of Windhover's 2004 Pharmaceutical Strategic Alliances conference was "transitions", the full subtext was "transitions to sustainability." Mid-sized players appear to have the best shot at sustainability in an environment where, increasingly, less differentiated, primary care blockbusters are out, and specialist products are in.

If the nominal theme of Windhover's 2004 Pharmaceutical Strategic Alliances conference was "transitions", the full subtext was "transitions to sustainability."

Sustainability would hardly seem to be a matter of much dispute when it comes to Big Pharma. But serious threats to it were at least tacitly acknowledged in various talks at PSA—which took place a week before Merck & Co. Inc. announced its decision to pull rofecoxib (Vioxx) from the market, driving a wholly unprepared for $2.55 billion hole in a P&L bracing for the 2006 loss of the US patent on $5.1 billion simvastatin (Zocor). Discussed in several presentations, Bayer AG will now try to survive as a medium-sized European specialist, having basically abandoned its US primary care business to the struggling Schering-Plough Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.